SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending after its latest earnings report, which revealed a revenue miss largely driven by a sharp decline in crypto trading volume, despite an EPS beat. The community is divided, with some viewing the dip as a long-term buying opportunity due to new product initiatives like prediction markets, while others raise concerns over valuation and slowing growth.

Lyft, Inc. engages in the provision and management of an online social rideshare community platform. It offers access to a network of shared bikes and scooters for shorter rides and first mile and last-mile legs of multimodal trips, information about nearby public transit routes, and Lyft Rentals to offer riders a view of transportation options when planning any trip. The company was founded by Marcus Cohn, John Zimmer, Rajat Suri, Matt van Horn, and Logan Green in 2007 and is headquartered in San Francisco, CA.

Lyft Inc - Ordinary Shares Cls A

Lyft Inc

Lyft is trending amidst a post-earnings sell-off, with discussions centered on its Q4 revenue miss and Q1 guidance, despite an EPS beat from a tax benefit and a newly authorized $1 billion share buyback; the community debates whether this reflects an overreaction or deep-seated concerns about autonomous vehicle disruption and competitive positioning against Uber.

Mattel, Inc. engages in the ownership of children's and family entertainment franchises. It operates through the following segments: North America, International, and American Girl. The North America and International segments focus on marketing and selling toys and consumer products. The American Girl segment includes marketing, retailing, and publishing dedicated to its mission to help girls grow up with confidence and character. The company was founded by Elliot Handler, Ruth Handler, and Harold Matson in 1945 and is headquartered in El Segundo, CA.

Mattel, Inc.

Mattel experienced a dramatic sell-off, with its stock hitting both a 52-week high and low in the same day, after reporting a Q4 earnings miss and a weaker FY26 profit outlook. While some are shocked by the decline, a significant portion of the community views the reaction as "overdone" and is "loading up" on what they perceive as a discounted buying opportunity, alongside news of the company acquiring full ownership of its Mattel163 mobile game studio.

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopify is drawing significant attention ahead of its imminent earnings report, fueling a strong debate among investors as many anticipate a powerful rebound driven by robust holiday sales and AI integration benefits, while others remain cautious about its high valuation amid a broader software sector pullback.

Ford Motor Co. engages in the manufacture, distribution, and sale of automobiles. It operates through the following segments: Ford Blue, Ford Model E, Ford Pro, Ford Next, Ford Credit, and Corporate Other. The Ford Blue, Ford Model E, and Ford Pro segment includes the sale of Ford and Lincoln vehicles, service parts, and accessories, together with the associated costs to develop, manufacture, distribute, and service the vehicles, parts, and accessories. The Ford Next segment is involved in the expenses and investments for emerging business initiatives aimed at creating value for Ford in vehicle-adjacent market segments. The Ford Credit segment consists of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities. The Corporate Other segment refers to corporate governance expenses, past service pension and OPEB income and expense, interest income and gains and losses from cash, cash equivalents, and marketable securities, and foreign exchange derivatives gains, and losses associated with intercompany lending. The company was founded by Henry Ford on June 16, 1903 and is headquartered in Dearborn, MI.

Ford Motor Co.

Ford Motor Co

Ford is actively trending after its Q4 earnings revealed a substantial net loss due to EV restructuring, but community discussion is primarily focused on the encouraging 2026 adjusted EBIT outlook and strong hybrid sales, which appear to be outweighing immediate performance concerns.

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Nektar Therapeutics

Nektar Therapeutics is trending following strong 52-week data for its atopic dermatitis drug, rezpegaldesleukin, which demonstrated durable and deepening responses, leading analysts to raise price targets and sparking community excitement over its competitive potential against Dupixent. Despite a recent public offering and mixed past results for alopecia areata, the drug's favorable safety profile and significant market opportunity are key discussion points, fueling speculation of a major pharmaceutical buyout.

The Charles Schwab Corp. is a savings and loan holding company, which engages in the provision of wealth management, securities brokerage, banking, asset management, custody, and financial advisory services. It operates through the Investor Services and Advisor Services segments. The Investor Services segment includes retail brokerage, investment advisory, and banking and trust services to individual investors, retirement plan and business services, as well as other corporate brokerage services, to businesses and employees. The Advisor Services segment provides custodial, trading, banking and trust, and support services to independent registered investment advisors, independent retirement advisors, and recordkeepers. The company was founded by Charles Robert Schwab in 1986 and is headquartered in Westlake, TX.

Charles Schwab Corp.

The financial services sector's reaction to new AI-powered tax planning tools from competitors is driving conversation around Charles Schwab, with the community debating the potential for disruption to traditional advisory models and viewing the sharp sell-off as a significant overreaction.

Cloudflare, Inc. engages in the provision of cloud-based services to secure websites. It offers various products for performance and reliability, video streaming and delivery, advanced security, insights, Cloudflare for developers, domain registration, and Cloudflare marketplace. It operates through the United States and Rest of the World geographical segments. The company was founded by Matthew Prince, Michelle Zatlyn, and Lee Holloway in July 2009 and is headquartered in San Francisco, CA.

Cloudflare Inc - Ordinary Shares - Class A

Cloudflare Inc

Cloudflare is trending due to a strong earnings beat and robust revenue guidance, with its CEO emphasizing the company's critical role as the "backbone of the agentic internet" amid surging AI demand, distinguishing its performance during a broader software sector downturn.

Lattice Semiconductor Corp. engages in the business of developing technologies that are monetized through differentiated programmable logic semiconductor products, system solutions, design services, and licenses. It also offers silicon-based and silicon-enabling products, evaluation boards, development hardware, and related intellectual property licensing, services, and sales. The company was founded in 1983 and is headquartered in Hillsboro, OR.

Lattice Semiconductor Corp.

Lattice Semiconductor is trending following its Q4 earnings, which showed a revenue beat and a strong forecast for the next quarter, exciting the community with significant options gains. Investors are keenly watching its momentum in AI, data centers, and its pivotal role in edge computing and robotics, though some anticipate profit-taking.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals is generating buzz due to observed large after-hours trading volumes and the imminent closure of its Astria Therapeutics acquisition, driving community debate over potential short covering and a long-awaited reversal, contrasting with ongoing investor frustration over sustained share price pressure and dilution concerns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Given Average Recommendation of "Moderate Buy" by Brokerages

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) has received an average rating of "Moderate Buy" from the five ratings firms that are covering the stock, MarketBeat.com reports. One...

Rani Therapeutics (NASDAQ:RANI) Stock Price Down 2.2% - What's Next?

Rani Therapeutics (NASDAQ:RANI) Trading Down 2.2% - Time to Sell...

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Consensus Rating of "Moderate Buy" from Analysts

Shares of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the five ratings firms that are covering the stock...

Rani Therapeutics (NASDAQ:RANI) Stock Price Up 1.3% - Here's Why

Rani Therapeutics (NASDAQ:RANI) Stock Price Up 1.3% - Here's Why...

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Given Average Recommendation of "Moderate Buy" by Analysts

Shares of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the five brokerages that are covering the stock...

Investors Purchase High Volume of Put Options on Rani Therapeutics (NASDAQ:RANI)

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) was the recipient of some unusual options trading activity on Thursday. Stock investors acquired 12,455 put options on the stock. This...

Rani Therapeutics (NASDAQ:RANI) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPS

Rani Therapeutics (NASDAQ:RANI - Get Free Report) released its earnings results on Thursday. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts' consensus...

Rani Therapeutics Holdings Inc. (RANI) on Friday announced that it has entered into a strategic collaboration with Chugai Pharmaceutical Co., aiming to advance the development of an oral therapeutic using its proprietary RaniPill technology.&nbsp;Chugai will work with Rani to create and commercialize a new oral product based on an experimental antibody for rare diseases. Under the deal, Rani will receive $10 million upfront.Beyond the upfront payment, Rani may earn up to $75 million in development-related milestones, another $100 million based on commercial achievements, and single-digit royalties on sales once the product reaches the market. The agreement grants Chugai an initial license for one drug target, with the possibility of expanding to five more. The total potential payments could reach $1.085 billion if all options are exercised.Following the announcement,&nbsp;<a href="https://stocktwits.com/symbol/RANI">Rani Therapeutics' stock</a> traded over 165% higher in Friday’s premarket. On Stocktwits, retail sentiment around the stock jumped to ‘extremely bullish’ from ‘bearish’ territory the previous day. Message volume shifted to ‘extremely high’ from ‘low’ levels in 24 hours.&nbsp;By partnering with Chugai, the company gains access to a promising rare disease pipeline while reinforcing its financial position.&nbsp;&nbsp;“There are many cases where oral therapies for the treatment of multiple disease areas with high unmet medical needs, including rare and immunologic diseases, are limited and as a result, patients rely primarily on injections that can be burdensome and impact adherence,” said Rani CEO, Talat Imran.&nbsp;&nbsp;In a parallel move, Rani announced a private placement financing expected to generate about $60.3 million in gross proceeds.Rani Therapeutics’ stock has lost over 65% in 2025 and over 82% in the past 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/stellantis-joins-hands-with-pony-ai-to-power-self-driving-vans-in-europe/ch6sdh6R3FD">Stellantis Stock Edges Up Premarket: Legacy Auto Giant Joins Hands With China's Pony AI To Power Self-Driving Vans In Europe</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Why Is Rani Therapeutics’ Stock Skyrocketing Pre-Market Today?

The total potential payments from the collaboration could reach $1.085 billion if all options are exercised.

Equity

The total potential payments from the collaboration could reach $1.085 billion if all options are exercised.


These five health care stocks, all belonging to small- or micro-cap categories, notched the highest jump in Stocktwits followers in the week ended Feb. 7, 2025:GH Research PLC (+103% jump in followers)&nbsp;GH Research PLC focuses on developing mebufotenin-based therapies for treatment-resistant depression. The company’s inhalable candidate, GH001, met its primary endpoint in a Phase 2b trial, showing a significant reduction in depression scores compared to placebo. Secondary endpoints also showed improvements, with no serious adverse events reported.&nbsp;Despite the promising data, GHRS stock fell more than 28% over the past week.Lipella Pharmaceuticals Inc. (+40% jump in followers)Lipella Pharmaceuticals received FDA approval for an Expanded Access Program for LP-310, an oral rinse for treating oral lichen planus. The condition affects around 6 million Americans and currently has no FDA-approved therapies. The program allows patients with serious unmet medical needs to access the treatment outside of clinical trials.&nbsp;Following the announcement, LIPO stock climbed nearly 14% last week.MBX Biosciences Inc. (+39% jump in followers)MBX Biosciences, focused on peptide therapies for endocrine and metabolic disorders, had no major catalyst last week. However, in January, the company reported positive results from a Phase 1 trial of its long-acting GLP-1 receptor antagonist, MBX 1416, which showed a favorable safety profile.&nbsp;MBX shares surged more than 25% over the past week.Rani Therapeutics Holdings Inc. (+29% jump in followers)Rani Therapeutics, which is developing oral alternatives to injectable biologics, shared new preclinical data on its RaniPill capsule for delivering semaglutide. The study showed successful drug delivery with bioavailability and weight-loss effects comparable to subcutaneous administration. The company plans to start Phase 1 trials of a GLP-1/GLP-2 dual agonist in 2025.&nbsp;RANI stock rose over 12% last week.Invivyd Inc. (+21% jump in followers)Invivyd, which focuses on monoclonal antibodies for viral diseases, reported positive data from its ongoing Phase 1/2 trial of VYD2311, a potential alternative to COVID-19 vaccines. The candidate showed strong antiviral activity and a promising safety profile. The data, combined with results from its Phase 3 CANOPY trial, support its potential as a long-acting COVID-19 treatment.&nbsp;Invivyd shares soared over 355% last week.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Woman examining laboratory samples - stock photo | Image source: Getty Images

These 5 Health Care Stocks Saw The Sharpest Retail Interest Jump Last Week

These five small-cap pharma and biotech stocks drew heavy attention on Stocktwits last week, driven by key trial results, FDA updates, and promising drug developments.

Rani Therapeutics Holdings, Inc. engages in the operation of a clinical stage bio-therapeutics company. The company was founded by Mir Imran on February 21, 2012 and is headquartered in San Jose, CA.

Rani Therapeutics Holdings Inc - Ordinary Shares Class A

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $SHOP earnings on Wednesday?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.05	--	--	N/A
Q3 '25	-$0.15	-$0.12	21.31%	BEAT
Q2 '25	-$0.28	-$0.18	36.84%	BEAT
Q1 '25	-$0.28	-$0.22	21.43%	BEAT
Q4 '24	-$0.27	-$0.27	-0.47%	MISSED

RANI
Rani Therapeutics Holdings Inc - Ordinary Shares Class A

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest RANI News

RANIRani Therapeutics Holdings Inc - Ordinary Shares Class A